<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315131</url>
  </required_header>
  <id_info>
    <org_study_id>TV46017-COPD-10046</org_study_id>
    <nct_id>NCT02315131</nct_id>
  </id_info>
  <brief_title>Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017</brief_title>
  <official_title>A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV46017</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to characterize the safety profile and duration of&#xD;
      bronchodilation of a single dose of inhaled TV46017&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision&#xD;
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-12h</measure>
    <time_frame>Baseline, 12 hours</time_frame>
    <description>baseline adjusted forced expiratory volume in 1 second area under the curve over 12 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>Baseline, 12 hours</time_frame>
    <description>baseline adjusted trough 12 hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD</condition>
  <arm_group>
    <arm_group_label>TV46017- Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1 includes a single-dose treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Healthy Volunteers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Some healthy subjects will be randomized to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV46017 15 μg- COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2 includes two 24 hour treatment periods with approximately 7 days of washout in between each treatment period; and open label ipratropium bromide pressurized metered-dose inhaler hydrofluoroalkane (HFA) will be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV46017 60 μg- COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV46017 120 μg- COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV46017 240 μg- COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV46017</intervention_name>
    <description>TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.</description>
    <arm_group_label>TV46017 120 μg- COPD</arm_group_label>
    <arm_group_label>TV46017 15 μg- COPD</arm_group_label>
    <arm_group_label>TV46017 240 μg- COPD</arm_group_label>
    <arm_group_label>TV46017 60 μg- COPD</arm_group_label>
    <arm_group_label>TV46017- Healthy Volunteers</arm_group_label>
    <other_name>46017</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo - Healthy Volunteers</arm_group_label>
    <other_name>Matching placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Stage 1 Inclusion Criteria (healthy volunteers):&#xD;
&#xD;
          -  The subject is a male or female 20 to 75 years of age, inclusive, weighing 50 to 80 kg&#xD;
             with a body mass index (BMI) of less than 30 kg/m2. Note: Every effort should be made&#xD;
             to enroll approximately equal numbers of men and women in each group.&#xD;
&#xD;
          -  The subject is in good health as determined by medical and psychiatric history,&#xD;
             physical examination, electrocardiogram (ECG), serum chemistry, hematology,&#xD;
             urinalysis, and serology.&#xD;
&#xD;
          -  Other criteria apply, please contact the investigator for more information&#xD;
&#xD;
        Stage 2 Inclusion Criteria (COPD patients):&#xD;
&#xD;
          -  Current or former cigarette smokers with a history of cigarette smoking of ≥10 pack&#xD;
             years at the SV (number of cigarette packs smoked per day multiplied by the number of&#xD;
             years smoked; eg, 2 packs/day for 3 years equals a 6 pack year history).&#xD;
&#xD;
          -  Diagnosis of COPD as defined by the Global Initiative for Chronic Obstructive Lung&#xD;
             Disease guidelines.&#xD;
&#xD;
          -  Male or female; 40 to 75 years of age, inclusive.&#xD;
&#xD;
          -  Patient is free of any other medical conditions or concomitant treatment that could&#xD;
             interfere with study conduct, influence the interpretation of study&#xD;
             observations/results, or put the patient at increased risk during the study.&#xD;
&#xD;
          -  Other criteria apply, please contact the investigator for more information&#xD;
&#xD;
        Stage 1 Exclusion Criteria (healthy volunteers):&#xD;
&#xD;
          -  History or current evidence of a clinically significant or uncontrolled disease.&#xD;
&#xD;
          -  Any disorder that may interfere with the absorption, distribution, metabolism or&#xD;
             excretion of study drugs.&#xD;
&#xD;
          -  History of severe allergy to milk protein.&#xD;
&#xD;
          -  Active smokers or former smokers who quit within 3 months of the first dose of study&#xD;
             drug. Former smokers with greater than five-pack years (ie, the equivalent of one pack&#xD;
             per day for five years) are also excluded.&#xD;
&#xD;
          -  Other criteria apply, please contact the investigator for more information&#xD;
&#xD;
        Stage 2 Exclusion Criteria (COPD patients):&#xD;
&#xD;
          -  Recent history of hospitalization due to an exacerbation of airway disease within 3&#xD;
             months.&#xD;
&#xD;
          -  Need for increased treatments of COPD within 6 weeks prior to the SV.&#xD;
&#xD;
          -  Occurrence of a COPD exacerbation, which is not resolved by 4 weeks or more prior to&#xD;
             the SV/informed consent. (Note: An exacerbation of COPD is defined as any worsening of&#xD;
             the patient's baseline COPD symptoms requiring any treatment other than rescue&#xD;
             albuterol or the patient's regular maintenance therapy. This includes requiring the&#xD;
             use of systemic corticosteroids, antibiotics, and/or emergency room visit or&#xD;
             hospitalization.)&#xD;
&#xD;
          -  History of and/or current diagnosis of asthma.&#xD;
&#xD;
          -  Known α1 antitrypsin deficiency, active lung infections (such as tuberculosis or&#xD;
             pneumonia), and lung cancer are absolute exclusionary conditions. A patient who, in&#xD;
             the opinion of the investigator, has any other significant respiratory condition in&#xD;
             addition to COPD should be excluded. Examples may include clinically significant&#xD;
             noncystic bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung&#xD;
             disease. Allergic rhinitis is not exclusionary.&#xD;
&#xD;
          -  Other criteria apply, please contact the investigator for more information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Branded Pharmaceutical Products R&amp;D, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 13033</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13034</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 78984</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 78985</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 79037</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 79036</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 79034</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>December 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

